Hydroxychloroquine Market, By Disease Indication (Malaria, Coronavirus Disease, Lupus Erythematosus, and Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin Am

Hydroxychloroquine Market, By Disease Indication (Malaria, Coronavirus Disease, Lupus Erythematosus, and Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hydroxychlorquine has exhibits the potential invitro activity against viruses including influenza, malaria, coronavirus, and many other diseases. The drug is under investigation to determine its efficacy for the treatment of novel coronavirus disease (COVID 19). According to the studies conducted in Wuhan, the body temperature recovery time and the cough remission time of coronavirus patients were significantly reduced with hydroxycloroquine and chloroquine treatment.
Despite the absence of strong evidence, the demand for hydroxychloroquine has spiked due to the coronavirus (COVID 19) outbreak. However, the doses of hydroxychloroquine need to be monitored, as its overdose can have dangerous side effects such as drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm, ventricular tachycardia, and ventricular fibrillation. This may lead to sudden respiratory and cardiac arrest, which can be fatal.
Market Dynamics
The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to evaluate the efficacy of hydroxchloroquine tablets for the treatment of patients with coronavirus disease (COVID 19) are expected to propel the market growth over the forecast period. For instance, on March 27, 2022, Rising Pharma Holdings Inc., a pharmaceutical company, entered into a collaborative agreement with the Division of Infectious Disease and International Medicine at the University of Minnesota, Department of Infectious Disease, to explore hydroxchloroquine as preventive treatment for coronavirus disease (COVID 19).
Key features of the study:
This report provides in-depth analysis of the global hydroxchloroquine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hydroxchloroquine market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, disease indication up-gradation, market expansion, and marketing tactics
The global hydroxchloroquine market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hydroxchloroquine market
Detailed Segmentation:
Global Hydroxchloroquine Market, By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
Global Hydroxchloroquine Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hydroxchloroquine Market, By Region:
North America
By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Disease Indication:
Malaria
Coronavirus disease (COVID 19)
Lupus Erythematosus
Rheumatoid Arthritis
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Sanofi S.A.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Amneal Pharmaceuticals, Inc.
Laurus Labs Limited
Zydus Pharmaceuticals, Inc.
Prasco Laboratories
Dr. Reddy's Laboratories
Cadila Pharmaceuticals
Novartis International AG
Concordia Pharmaceuticals Inc.
Covis Pharmaceuticals, Inc.
Cardinal Health
Aphena Pharma Solutions Tennessee, Inc.
Mylan N.V.
McKesson Corporation
Teva Pharmaceutical Industries Ltd
Lupin Pharmaceutical
Sun Pharmaceutical Industries Ltd
“*” marked represents similar segmentation in other categories in the respective section.